Dominic Muston

4PUBLICATIONS
7CO-AUTHORS
Predictive and prognostic markersEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Nov 05, 2024
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.

Bradley J Monk, Sophie van Mens, Oliver Hale

|May 21, 2024
Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit.

Dominic Muston

|May 26, 2023
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.

David Elsea, Dominic Muston, Lin Fan

|Aug 15, 2020
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Wei Gao, Dominic Muston, Matthew Monberg

Pageof 1

Frequent Collaborators

1 joint publications

R Brett McQueen

1 joint publications

Bradley J Monk

1 joint publications

Oliver Hale

1 joint publications

Jennifer Boer